Discovery of T-type calcium channel antagonists from multicomponent reactions and their application in paclitaxel-induced peripheral neuropathy
Ended Project Grant Awarded Last action
- Award ID
- R41NS116784
- Recipient
-
Regulonix LLC UEI RZ32MNG7DH93
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $341,527
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Arizona, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $341,527 |
Quick answers
Who received award R41NS116784?
R41NS116784 was awarded to Regulonix LLC by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 30, 2019.
How much is award R41NS116784 worth?
$341,527 has been obligated on R41NS116784.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award